Macromoltek applies computational modeling and artificial intelligence to antibody design and engineering for biotech and pharmaceutical partners. The company works across the drug development pipeline, from early-stage target identification through lead optimization, helping clients reduce time-to-market and improve the probability of clinical success.
The company offers three core services: AI-driven antibody discovery to identify promising candidates faster; computational structure modeling to predict and refine antibody structures; and custom antibody engineering partnerships where clients collaborate directly with Macromoltek's team to develop antibodies tailored to specific targets. This integrated approach aims to reduce experimental cycles and overall risk in the drug development process whilst enabling the design of highly specific and effective antibodies.